Posted in | News | Business

Enevate Announces New Production License Agreement that will Drive its Breakthrough Battery Technology to Production as Early as 2022

Enevate, a pioneering battery innovation company featuring extreme fast charge and high energy density battery technologies for electric vehicles (EVs) and other markets, announced a new production license agreement with EnerTech International to commercialize Enevate's silicon-dominant, XFC-Energy™ battery technology in the transportation, mobility and reserve power markets.

South Korea-based EnerTech International is a leader in delivering lithium-ion cells using state-of-the-art manufacturing facilities to high-performance, large format batteries in demand by today’s rapidly growing markets.

This production license agreement with EnerTech is the next milestone in Enevate's technology roadmap that leads to commercialization scheduled for 2022. Pre-production batteries have been built and tested using EnerTech's existing lithium-ion battery manufacturing equipment. With the agreement, Enevate will deliver enabling technology to accelerate EnerTech's market expansion and triple its manufacturing capacity output.

Enevate's next-gen lithium-ion battery technology delivers up to 10 times faster charging than conventional lithium-ion batteries with high energy densities along with a host of other benefits, including improved safety and low-temperature operation for cold climates. With its Extreme Fast Charge capability, Enevate technology allows for a battery to charge in as fast as five minutes.

"Combining EnerTech's world-class manufacturing base with Enevate's revolutionizing technology will enable our growth plans across multiple segments as we match development pace with our customers' ever-increasing battery specification requirements, now and into the future," said Duke Oh, CEO EnerTech International.

"This production license agreement with EnerTech represents another step toward establishing Enevate technology as the de facto standard for offering fast charge, high energy density, and improved safety," said Enevate CEO Robert A. Rango. "The next-generation battery technology is here today."

As the global advanced battery markets push the limits of battery technology, cost targets remain a critical parameter to making next-generation battery technology accessible and affordable to everyone. Therefore, technology versatility and manufacturability are necessary, and those attributes are defining features of Enevate's technology. Enevate's breakthrough battery technology is compatible with lithium-ion cathode chemistries plus solid-state electrolytes and is manufacturable using existing production lines and capital equipment.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Enevate Corporation. (2021, June 09). Enevate Announces New Production License Agreement that will Drive its Breakthrough Battery Technology to Production as Early as 2022. AZoM. Retrieved on November 21, 2024 from https://www.azom.com/news.aspx?newsID=56269.

  • MLA

    Enevate Corporation. "Enevate Announces New Production License Agreement that will Drive its Breakthrough Battery Technology to Production as Early as 2022". AZoM. 21 November 2024. <https://www.azom.com/news.aspx?newsID=56269>.

  • Chicago

    Enevate Corporation. "Enevate Announces New Production License Agreement that will Drive its Breakthrough Battery Technology to Production as Early as 2022". AZoM. https://www.azom.com/news.aspx?newsID=56269. (accessed November 21, 2024).

  • Harvard

    Enevate Corporation. 2021. Enevate Announces New Production License Agreement that will Drive its Breakthrough Battery Technology to Production as Early as 2022. AZoM, viewed 21 November 2024, https://www.azom.com/news.aspx?newsID=56269.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.